Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 20, 2022

SELL
$1.73 - $4.06 $21,218 - $49,795
-12,265 Closed
0 $0
Q4 2021

Feb 15, 2022

BUY
$3.5 - $5.68 $42,927 - $69,665
12,265 New
12,265 $38,000
Q1 2021

Apr 28, 2021

SELL
$4.9 - $6.83 $121,863 - $169,862
-24,870 Closed
0 $0
Q4 2020

Jan 27, 2021

BUY
$4.0 - $9.2 $56,712 - $130,437
14,178 Added 132.6%
24,870 $139,000
Q3 2020

Nov 06, 2020

BUY
$7.66 - $10.78 $81,900 - $115,259
10,692 New
10,692 $56,000

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $111M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Chicago Partners Investment Group LLC Portfolio

Follow Chicago Partners Investment Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Chicago Partners Investment Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Chicago Partners Investment Group LLC with notifications on news.